|
|
Sign up for Email Notifications
If you would like to be notified when submission deadlines are announced please click on the appropriate link below.
Alzheimer's Disease Research
Macular Degeneration Research
National Glaucoma Research
This email list is not sold or distributed, and serves only as an annual reminder of the availability of research funding through the American Health Assistance Foundation (www.ahaf.org). Please follow instructions on the notification emails for removal requests.
|
|
|
|
Alzheimer's Disease Research - Current Awards
|
|
Paul Axelsen, M.D.
University of Pennsylvania
Philadelphia, PA
Title: Oxidative stress and amyloidogenesis
Non-Technical Title: The chemistry of Alzheimer's disease
Duration: April 1, 2008 - March 31, 2010
Award Type: Pilot
$187,500 |
| |
Oxidative stress and amyloid fibril formation are consistent major themes among processes thought to be involved in the pathogenesis of Alzheimer's disease. However, a mechanistic link between these two processes has not been defined. The research being proposed will probe human brain tissues and animal models of Alzheimer's disease for evidence of a specific chemical mechanism that will be amenable to therapeutic intervention.
More details |
|
|
|
Randall Bateman, M.D.
Washington University
St. Louis, MO
Title: Human CNS-Apolipoprotein E Isoform Production and Clearance
Non-Technical Title: Metabolism of the protein (ApoE) that increases risk of Alzheimer's Disease in humans.
Duration: April 1, 2008 - March 31, 2010
Award Type: Pilot
$150,000 |
| |
Although te ApoE is the strongest genetic risk factor for Alzheimer's disease, relatively little is known about the how ApoE contributes to that risk. This study seeks to characterize basic biological differences between three different ApoE alleles.
More details |
|
|
|
Gal Bitan, Ph.D.
University of California, Los Angeles
Los Angeles, CA
Title: Rational design of amyloid beta-protein aggregation and toxicity inhibitors
Non-Technical Title: Rational design of novel drugs for Alzheimer's disease
Duration: April 1, 2008 - March 31, 2010
Award Type: Pilot
$100,000 |
| |
In this project we will use a novel approach that combines our most current understanding of the molecular processes that lead to AD. We do that by "tailoring" sophisticated weapons that target what is believed to be the very first event along the pathway that leads to formation of the toxic molecules that rob AD patients of their memory and personality.
More details |
|
|
|
Anne Cataldo, Ph.D.
McLean Hospital
Belmont, MA
Title: A Novel Treatment Strategy for Neurorepair in Alzheimer's Disease
Non-Technical Title: The Use of Adult Bone Marrow Stem Cells in Treating Alzheimer's Disease
Duration: April 1, 2008 - March 31, 2010
Award Type: Pilot
$150,000 |
| |
In this project, 'adult' stem cells will be used as a delivery system to deliver sAPP to brain regions undergoing neurodegeneration. The hypothesis is that sAPP will work together with growth factors to protect and repair cholinergic neurons in the brain, thereby representing a potential for therapeutic treatment in humans with AD.
More details |
|
|
|
Erin Congdon, Ph.D.
Research Foundation For Mental Hygiene
New York, NY
Title: Tau Dissociation As A Therapeutic Approach For Tauopathy
Non-Technical Title: Untangling Tau As An Approach To Treating Tangles In AD
Duration: April 1, 2009 - March 31, 2011
Award Type: Research Fellowship
$100,000 |
| |
Aggregated tau accumulated in tangles is a major feature of the Alzheimer’s disease affected brain. These accumulations are thought to be highly toxic to neurons. Aggregated tau can be disassociated in test tubes by several compounds including cyanine dyes. We aim to test the therapeutic potential of a cyanine dye both in living systems and in living system models of disease.
More details |
|
|
|
Marta Cortes-Canteli, Ph.D.
Rockefeller University
New York, NY
Title: Role Of Amyloid Beta-Fibrinogen Interaction In Alzheimer's Disease
Non-Technical Title: Blood Clots In The Alzheimer's Disease Brain
Duration: April 1, 2009 - March 31, 2011
Award Type: Research Fellowship
$100,000 |
| |
Amyloid beta interacts with fibrinogen in test tubes and prevents fibrin clots from degrading. Studying this phenomenon in living systems in addition to the role of ApoE in disease pathology will help to clarify the role of fibrin in the abnormal cerebral vasculature in Alzheimer's disease.
More details |
|
|
|
Pritam Das, Ph.D.
Mayo Clinic Jacksonville
Jacksonville, FL
Title: Cytokine Modulation Of Amyloid Beta Associated Pathologies In APP Mouse Models Of Alzheimer's Disease
Non-Technical Title: Effect Of Inflammation In The Brain On Disease Progression In Alzheimer’s Disease
Duration: April 1, 2009 - March 31, 2012
Award Type: Standard
$399,999 |
| |
The experiments proposed here will establish an experimental template to study potential disease modifiers, their roles in modulating Alzheimer’s disease (AD) like pathologies and their use in the future design of potential AD therapeutics.
More details |
|
|
|
Kelley Dineley, Ph.D.
University of Texas Medical Branch
Galveston, TX
Title: PPAR-Gamma Rescue Of Cognitive Function In Alzheimer's Disease
Non-Technical Title: Insulin Regulatory Gene In The Central Nervous System Mediates Cognitive Function In Alzheimer's Disease
Duration: April 1, 2009 - March 31, 2012
Award Type: Standard
$399,000 |
| |
Our preliminary studies have discovered a role for a gene called PPAR-gamma in cognitive function in Alzheimer's disease. Since virtually nothing is known about PPAR-gamma regulation in the brain, the specific aims of this project are to define the PPAR-gamma signaling axis in brain regions that underlie the types of cognitive function that PPAR-gamma agonism improves.
More details |
|
|
|
Luciano Domenici, M.D., Ph.D.
National Council of Research (C.N.R.)
Pisa, Italy
Title: RAGE, MAP kinases and Abeta induced synaptic dysfunction
Non-Technical Title: Role of RAGE in Alzheimer's disease
Duration: April 1, 2008 - March 31, 2010
Award Type: Pilot
$148,000 |
| |
Nerve signaling dysfunctions triggered by ABeta are central to AD progression. This study will lead to a better understanding of these processes, in particular, RAGE signaling. Results of this study will facilitate design of therapeutic agents that prevent or minimize the actions of ABeta on nerve signaling.
More details |
|
|
|
J. Kevin Foskett, Ph.D.
University of Pennsylvania
Philadelphia, PA
Title: IP3R-Presenilin Interaction: Calcium Dysregulation in AD
Non-Technical Title: Calcium disruption in Alzheimer's Disease
Duration: April 1, 2008 - March 31, 2011
Award Type: Standard
$400,000 |
| |
This study is designed to test how presenilin interacts with calcium signaling proteins, resulting in changes to the presenilin function. The study will also examine how altered calcium signaling in turn affects other cell functions. These studies should provide new insights into the molecular mechanisms of AD and into the development of novel targets for therapeutic interventions.
More details |
|
Last Reviewed On: 05/12/09
|
